Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights into global market size, regional shares, competitor strategies, and market opportunities. It offers a thorough analysis of current and future industry scenarios.
The liposomal doxorubicin market has exhibited robust growth, projected to expand from $1.32 billion in 2025 to $1.41 billion in 2026 at a CAGR of 6.8%. This upward trend is driven by limitations in conventional doxorubicin toxicity, increasing cancer incidence globally, early adoption of liposomal drug delivery systems, and a growing preference for hospital-based chemotherapy. Furthermore, expanding oncology treatment protocols contribute significantly to this growth.
Looking forward, the market is expected to grow to $1.77 billion by 2030 with a CAGR of 5.9%, spurred by the demand for safer cancer therapies, a heightened focus on patient quality of life, and improved access to oncology treatments in emerging markets. Key trends include the rising use of liposomal drugs to mitigate cardiotoxicity and the preference for targeted chemotherapy, particularly in ovarian and breast cancer treatments. The expansion of generic liposomal doxorubicin products further boosts market activity.
Cancer incidence is a critical growth driver for this market. Increases in cancer cases are linked to an aging population, lifestyle changes, environmental factors, and advances in diagnostic technologies. For instance, the American Cancer Society recorded an increase in cancer cases to 2,001,140 in 2024, illustrating a growth trend of 2.19% from the previous year. Liposomal doxorubicin plays a pivotal role in cancer therapy by enhancing drug delivery, reducing toxicity, and improving patient outcomes.
Key players in this market are innovating with liposomal injectable formulations, such as ready-to-use products, aiming to improve therapeutic indices, lower toxicity, and streamline hospital administration. For example, ForDoz Pharma Corp. introduced FDA-approved DOXOrubicin Hydrochloride Liposome Injection as a convenient ready-to-use product for treating ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. This formulation ensures sustained, tumor-targeted drug delivery with reduced peak-related toxicity, aiding in treatment optimization.
Recent strategic movements include CHEPLAPHARM Arzneimittel GmbH's acquisition of Myocet, a non-pegylated liposomal doxorubicin from Teva Pharmaceutical Industries Ltd., enhancing their oncology portfolio. The market also features prominent companies like Johnson & Johnson, Pfizer Inc., and Sun Pharmaceutical Industries Ltd., focusing on innovation and expansion.
Regionally, North America led the market in 2025, with Asia-Pacific poised for the fastest growth. The market dynamics are also shaped by tariffs, which have increased costs but boosted regional production capabilities for generic alternatives. The regions monitored include Asia-Pacific, Europe, and North America, among others, with specific countries like the USA, China, and Germany highlighted for their market participation.
Advantages of Purchasing:
- Understand growth segments for strategic investment.
- Stay ahead of competitors using forecast data and market drivers.
- Analyze customer profiles based on end-user analysis.
- Benchmark your performance against leading competitors by market share and brand strength.
- Evaluate market potential with a total addressable market and attractiveness scoring.
Markets Covered:
- By Product: Doxil or Caelyx, Lipodox, Myocet, and other products
- By Application: Breast Cancer, Kaposi Sarcoma, and others
- By End-Users: Hospitals, Homecare, and more
Included regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Data is presented in a dynamic format including Word, PDF, and interactive Excel dashboards.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.41 Billion |
| Forecasted Market Value (USD) by 2030 | $1.77 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
The companies featured in this Liposomal Doxorubicin market report include:
- Johnson & Johnson
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Lupin Limited
- Zydus Lifesciences Ltd.
- Accord Healthcare Limited
- Dr. Reddy's Laboratories Ltd.
- Hikma Pharmaceuticals PLC
- Intas Pharmaceuticals Ltd.
- Mylan N.V.
- Apotex Inc.
- Natco Pharma Limited
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- TTY Biopharm Company Limited
- CSPC Pharmaceutical Group Limited
- Luye Pharma Group Ltd.
- Qilu Pharmaceutical Co. Ltd.
- Chia Tai Tianqing Pharmaceutical Group
- SRS Life Sciences
For more information about this report visit https://www.researchandmarkets.com/r/cm6mho
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
